Chiu Ya-Lin, Dinesh Chimmanamada U, Chu Chia-ying, Ali Akbar, Brown Kirk M, Cao Hong, Rana Tariq M
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Chem Biol. 2005 Jun;12(6):643-8. doi: 10.1016/j.chembiol.2005.04.016.
RNA interference (RNAi) is a process whereby short-interfering RNAs (siRNA) silence gene expression in a sequence-specific manner. We have screened a chemical library of substituted dihydropteridinones and identified a nontoxic, cell permeable, and reversible inhibitor of the RNAi pathway in human cells. Biochemical and fluorescence resonance-energy transfer experiments demonstrated that one of the compounds, named ATPA-18, inhibited siRNA unwinding that occurred within 6 hr of siRNA transfection. Extracts prepared from ATPA-18-treated cells also exhibited a decrease in target RNA cleavage by activated RNA-induced silencing complex (RISC*). Interestingly, when activated RISC*, which harbors unwound antisense siRNA, was treated with ATPA-18 in vitro, target RNA cleavage was not affected, indicating that this compound inhibited siRNA unwinding or steps upstream of unwinding in the RNAi pathway. Our results also establish the timing of siRNA unwinding and show that siRNA helicase activity is required for RNAi. ATPA-18 analogs will therefore provide a new class of small molecules for studying RNAi mechanisms in a variety of model organisms and deciphering in vivo genetic functions through reverse genetics.
RNA干扰(RNAi)是一个过程,通过该过程,短干扰RNA(siRNA)以序列特异性方式使基因表达沉默。我们筛选了一个取代二氢蝶啶酮的化学文库,并鉴定出一种无毒、可透过细胞且可逆的人类细胞RNAi途径抑制剂。生化和荧光共振能量转移实验表明,其中一种名为ATPA-18的化合物抑制了siRNA转染后6小时内发生的siRNA解旋。从经ATPA-18处理的细胞中制备的提取物也显示,活化的RNA诱导沉默复合体(RISC*)对靶RNA的切割减少。有趣的是,当含有解旋后的反义siRNA的活化RISC*在体外用ATPA-18处理时,靶RNA切割不受影响,这表明该化合物抑制了RNAi途径中的siRNA解旋或解旋上游的步骤。我们的结果还确定了siRNA解旋的时间,并表明RNAi需要siRNA解旋酶活性。因此,ATPA-18类似物将为研究多种模式生物中的RNAi机制以及通过反向遗传学解读体内遗传功能提供一类新的小分子。